Close Menu

NEW YORK (GenomeWeb News) – Investment firm Credit Suisse has initiated coverage of six companies operating in the life science tools and molecular diagnostics space.

On Wednesday analyst Vamil Divan initiated coverage on Illumina, Life Technologies, Thermo Fisher Scientific, Cepheid, Qiagen, and Waters.

Illumina was given a Neutral rating and a $30 target price on its stock. Divan estimated 2011 revenues at $1.05 billion, and 2012 revenues at $1.07 billion. He provided an EPS estimate for 2011 at $1.20 and for 2012 at $1.29.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.